mucosa, i.e. Ta. The sessile tumor extended well into the muscularis propria and the color of the underlying muscle was altered (Fig. 5) .
The pathology report showed a high grade muscle invasive urothelial cancer with lymphovascular invasion, pT3, and a papillary low grade (grade 2) tumor confined to the urothelium, pTa.
I had a lengthy discussion with the patient and they preferred to consider a bladder preservation approach. He received 4 cycles of gemcitabine and cisplatin. He tolerated this well despite the reduced renal function.
A flexible cystoscopy after two cycles revealed no evident tumor and a negative urinary cytology. The patient and family elected to observe and not proceed with radiation therapy.
An office cystoscopy in May 2017 indicated a subtle change at the prior tumor location and a TUR bladder tumor was performed (Figs. 6 and 7). This revealed persistent high grade muscle invasive urothelial cancer. A CT scan identified a 1 cm left pelvic lymph node and was otherwise free of metastasis. The patient now consented to a cystoprostatectomy.
The patient has a solitary right kidney, has some reduction in his renal function and is overweight (250 lbs.). The patient now consents to undergo a radical cystoprostatectomy. He has medical clearance. Would you perform an ileal conduit or consider a cutaneous ureterostomy? The advantage of the latter, assuming the ureter appears healthy and will easily reach the abdominal wall, would be a shorter operative time, no need for a bowel anastomosis and thus possible accelerated recovery, and omitting an anastomosis between the ureter and the ileum with a risk of subsequent stricture. The disadvantage might be stricture of the cutaneous ureterostomy site. The final pathology revealed a muscle invasive urothelial cancer with transmural extention to the serosa, pT3b, with two of 14 lymph nodes containing metastatic urothelial cancer. Is there a role for adjuvant therapy?
We invite our readers to review and comment on the case and management by using the online comment section below the case: https://www. bladdercancerjournal.com/challenging-cases
